The approval of Bolinger COPD by FDA keeps pace with the market

Source: dxy-2014-08-04 FDA approved strivedi respimat, a new type of inhaler for COPD, once a day The German pharmaceutical company hopes to make a foothold in the competitive respiratory drug market with this device The drug used in the inhaler, olodaterol, is a long-acting β - 2 receptor agonist (Laba), which can relax respiratory muscles and prevent lung diseases, such as chronic bronchitis and emphysema The U.S Food and Drug Administration approved the sale of bringer's COPD drug, the third leading cause of death in the United States, and like other Laba drugs, strivedi will have a black box warning that details its fatal risk associated with asthma The FDA approved the drug in October in Europe, bringing bringer into the world's largest chronic obstructive pulmonary disease market, but with the emergence of a new generation of treatments, the company is likely to face a tough battle Last year, a U.S FDA advisory panel signed a safety and effectiveness label for strivedi, but little was said to distinguish it from other drugs on the market, including GlaxoSmithKline's upcoming advair At the same time, GlaxoSmithKline has hit the market with anoro ellipta The drug combines the unique Laba and an independent long-acting muscarinic antagonist (Lama) to form a new compound preparation of COPD Analysts expect that the drug will eventually dominate part of the market Moreover, due to the sufficient budget, AstraZeneca is not willing to lag behind It has invested US $1.5 billion and US $2.1 billion respectively in Perl medical company and the upper respiratory business of almirall, and successively obtained some three-stage chronic obstructive pulmonary disease drugs Novartis' fixed dose of Laba / Lama, called ultibro breezhaler, also won European approval last year Bringer later came to think that his COPD drugs could surpass other competitors The company is awaiting FDA approval for a combination of olodaterol and Lama bronchiectasis agent tiotropium bromide, which is already approved as silivere Bringer's main three phase results revealed in May showed that the combination beat the placebo and each drug in the combination itself in improving lung function over a six week course Chronic obstructive pulmonary disease affects about 270000 people in the United States alone, and Citigroup expects such markets to rise from $10 billion in 2013 to $14 billion in 2018 Source address: http://